[go: up one dir, main page]

ATE66817T1 - Stabile formulierung biologisch aktiver proteine zur parenteralen injektion. - Google Patents

Stabile formulierung biologisch aktiver proteine zur parenteralen injektion.

Info

Publication number
ATE66817T1
ATE66817T1 AT86307397T AT86307397T ATE66817T1 AT E66817 T1 ATE66817 T1 AT E66817T1 AT 86307397 T AT86307397 T AT 86307397T AT 86307397 T AT86307397 T AT 86307397T AT E66817 T1 ATE66817 T1 AT E66817T1
Authority
AT
Austria
Prior art keywords
parenteral injection
biologically active
active proteins
stable formulation
formulation
Prior art date
Application number
AT86307397T
Other languages
English (en)
Inventor
James William Thomson
Original Assignee
Cetus Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cetus Corp filed Critical Cetus Corp
Application granted granted Critical
Publication of ATE66817T1 publication Critical patent/ATE66817T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT86307397T 1985-09-26 1986-09-25 Stabile formulierung biologisch aktiver proteine zur parenteralen injektion. ATE66817T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/780,551 US4816440A (en) 1985-09-26 1985-09-26 Stable formulation of biologically active proteins for parenteral injection
EP86307397A EP0217645B1 (de) 1985-09-26 1986-09-25 Stabile Formulierung biologisch aktiver Proteine zur parenteralen Injektion

Publications (1)

Publication Number Publication Date
ATE66817T1 true ATE66817T1 (de) 1991-09-15

Family

ID=25119894

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86307397T ATE66817T1 (de) 1985-09-26 1986-09-25 Stabile formulierung biologisch aktiver proteine zur parenteralen injektion.

Country Status (7)

Country Link
US (1) US4816440A (de)
EP (1) EP0217645B1 (de)
JP (1) JPS6272625A (de)
AT (1) ATE66817T1 (de)
AU (1) AU590618B2 (de)
CA (1) CA1295245C (de)
DE (1) DE3681243D1 (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0645551B2 (ja) * 1986-01-07 1994-06-15 塩野義製薬株式会社 インタ−ロイキン−２組成物
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
US5037644A (en) * 1986-10-27 1991-08-06 Cetus Corporation Pharmaceutical compositions of recombinant interleukin-2 and formulation processes
US4973478A (en) * 1987-07-20 1990-11-27 Allelix Biopharmaceuticals, Inc. Treating inflammation with hepatocyte stimulating factor interferon β2
NZ226799A (en) * 1987-11-06 1991-08-27 Oncogen Breast cancer inhibitory factor and method for inhibiting proliferation of neoplastic cells and compositions therefor
US4965191A (en) * 1988-02-12 1990-10-23 Eastman Kodak Company Lower alcohol sulfate wash solution, test kit and method for the determination of an immunological ligand
US5198212A (en) * 1988-10-31 1993-03-30 University Of Lousville Research Foundation Incorporated Method and compositions for treatment of trauma-associated sepsis with gamma interferon
US5530100A (en) * 1990-05-07 1996-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Methods for purification of recombinantly produced proteins
US5830452A (en) * 1990-11-20 1998-11-03 Chiron Corporation Method for enhancing the anti-tumor therapeutic index of interleukin-2
JPH0588553U (ja) * 1991-10-04 1993-12-03 チェン ロン−シウン 浮玉自動オフ式点滴輸液管
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US5545723A (en) * 1994-03-15 1996-08-13 Biogen Inc. Muteins of IFN-β
US5714371A (en) * 1995-05-12 1998-02-03 Schering Corporation Method for refolding insoluble aggregates of hepatitis C virus protease
IL135186A0 (en) 1997-09-23 2001-05-20 Rentschler Biotechnologie Bmgh LIQUID INTERFERON-β FORMULATIONS
US7582311B1 (en) 1999-10-15 2009-09-01 Genentech, Inc. Injection vehicle for polymer-based formulations
US7651703B2 (en) * 1999-10-15 2010-01-26 Genentech, Inc. Injection vehicle for polymer-based formulations
EP1935431A3 (de) 2000-05-15 2008-08-13 Health Research, Inc. Krebsbehandlungen unter Verwendung einer Kombination aus einem HER2-Antikörper und Interleukin-2
US7544354B2 (en) * 2000-10-27 2009-06-09 Novartis Vaccines And Diagnostics Methods of protein purification and recovery
PT1343518E (pt) * 2000-11-07 2009-08-03 Novartis Vaccines & Diagnostic Composições de interferão estabilizadas
US6887462B2 (en) 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US7745488B2 (en) * 2001-04-18 2010-06-29 Prometic Biosciences, Inc. Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
CA2502378A1 (en) * 2002-10-29 2004-05-13 Alza Corporation Stabilized, solid-state polypeptide particles
JP2006519170A (ja) * 2002-12-26 2006-08-24 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド サイトカイン、ケモカイン、増殖因子、ポリペプチドホルモン、およびレセプター結合活性が保存されたそのアンタゴニストのポリマー結合体
CN102319437B (zh) * 2002-12-26 2017-10-13 山景医药公司 具有增强的生物学效用的干扰素‑β的聚合物缀合物
WO2005042016A2 (en) * 2003-10-23 2005-05-12 Chiron Corporation Stabilised compositions
EP2149585B1 (de) 2003-11-04 2013-08-14 Novartis Vaccines and Diagnostics, Inc. Verwendung von antagonistischen anti-CD40-monoklonale Antikörper
US20070179113A1 (en) * 2005-05-19 2007-08-02 Schering Aktiengesellachaft GM-CSF gene therapy for Crohn's disease using an improved regulated expression system
DOP2006000117A (es) * 2005-05-19 2007-11-30 Schering Ag Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada
US20080076729A1 (en) * 2005-05-19 2008-03-27 Schering Aktiengesellachaft Interferon-beta gene therapy using an improved, regulated expression system
KR20080030956A (ko) * 2005-05-19 2008-04-07 바이엘 쉐링 파마 악티엔게젤샤프트 개선된 조절 발현 체계를 사용한 질병의 치료
US8273561B2 (en) * 2007-10-05 2012-09-25 Nuron Biotech, Inc. High pressure treatment of aggregated interferons
DE102012101864A1 (de) * 2012-03-06 2013-09-12 Gramme-Revit Gmbh Mittel zur Behandlung von Allergien und anderen Erkrankungen
US10961310B2 (en) 2017-03-15 2021-03-30 Pandion Operations, Inc. Targeted immunotolerance
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3658970A (en) * 1969-07-23 1972-04-25 John Mcclure Carroll Injectable lauric acid
US3667929A (en) * 1969-07-30 1972-06-06 George W Fleming Jr Method of effecting dissolution of solutes in water and compositions therefor
CA1113926A (en) * 1975-08-27 1981-12-08 Johannes Van Der Vies Pharmaceutical preparation adapted for oral administration
US4331653A (en) * 1977-08-18 1982-05-25 Robert Brown Composition for a topical cream for curtailing bleeding and treating skin disorders
JPS56104812A (en) * 1980-01-23 1981-08-20 Sankyo Co Ltd Production of cephalosporin compound preparation for rectal infusion
JPS5780314A (en) * 1980-11-09 1982-05-19 Kyoto Yakuhin Kogyo Kk Pharmaceutical preparation to be medicated to rectum
JPS5788126A (en) * 1980-11-19 1982-06-01 Kyoto Yakuhin Kogyo Kk Agent for promoting peroral and transvaginal absorption and preparation containing the same
JPS58116498A (ja) * 1981-12-28 1983-07-11 Takeda Chem Ind Ltd Ｉｌ‐２をコードする新規伝令ｒｎａの製造法
US4450103A (en) * 1982-03-01 1984-05-22 Cetus Corporation Process for recovering human IFN-β from a transformed microorganism
DE3377363D1 (en) * 1982-03-31 1988-08-18 Ajinomoto Kk Gene coding for interleukin-2 polypeptide, recombinant dna carrying said gene, cell lines possessing the recombinant dna,and method for producing interleukin-2 using said cells
US4462940A (en) * 1982-09-23 1984-07-31 Cetus Corporation Process for the recovery of human β-interferon-like polypeptides
US4463940A (en) * 1982-10-18 1984-08-07 Mock Russell V Apparatus and method for continuous stacking of signatures using opposed floating conveyors
EP0127426A1 (de) * 1983-05-23 1984-12-05 Takeda Chemical Industries, Ltd. Perkutane pharmazeutische Zusammensetzungen zur äusserlichen Anwendung
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2

Also Published As

Publication number Publication date
US4816440A (en) 1989-03-28
EP0217645A2 (de) 1987-04-08
AU6318286A (en) 1987-04-02
EP0217645A3 (en) 1987-09-23
CA1295245C (en) 1992-02-04
EP0217645B1 (de) 1991-09-04
JPS6272625A (ja) 1987-04-03
AU590618B2 (en) 1989-11-09
DE3681243D1 (de) 1991-10-10

Similar Documents

Publication Publication Date Title
ATE66817T1 (de) Stabile formulierung biologisch aktiver proteine zur parenteralen injektion.
DE3689870D1 (de) Formulierung für rekombinantes beta-Interferon, Verfahren zur Gewinnung und Stabilisierung des beta-Interferons und dessen Verwendung.
ATE66614T1 (de) Insulinzubereitung fuer nicht-parenterale verabreichung.
ATE74512T1 (de) Pharmazeutische zusammensetzungen von rekombinanten interleukin-2 und herstellungsverfahren.
FI874706A0 (fi) Menetelmä glykosyloimattoman yhdistelmäinterferoni- :n stabiilien, farmaseuttisten koostumusten valmistamiseksi
DE69531314D1 (de) Verwendung von metallionen chelatoren zur stabilisierung von interferon-enthaltenden pharmazeutischen zubereitungen
PH22556A (en) Heterocyclic compounds, pharmaceutical compositions containing the same and method of use thereof
MY128629A (en) Stabilized interleukin 2
ATE50256T1 (de) Hypoglycemische thiazolidinedione.
DE3684220D1 (de) Zusammensetzung mit verzoegerter abgabe.
ATE96807T1 (de) Rcrf und aehnliche verbindungen.
ES2009216A6 (es) Metodo de preparar un derivado de interleucina-lalfa.
ATE44652T1 (de) Zubereitung mit gehalt an stabilisiertes polypeptid mit gamma-interferon aktivitaet.
FI882605A0 (fi) Menetelmä, jonka avulla voidaan valmistaa suuren spesifisen tilavuusaktiivisuuden omaavaa liuosta proteiinista, jolla on kudosplasminogeeniaktivaattori(t-PA)-aktiivisuutta
SE8404065D0 (sv) Novel biologically active compounds
ES2009215A6 (es) Procedimiento de preparar un derivado de interleucina-1beta.
DK0641216T3 (da) Farmaceutisk præparat indeholdende IL-6
ATE79267T1 (de) Stabilisierung eines fuer therapeutische zwecke bestimmten interleukin-2-praeparates.
BG60101B2 (bg) Метод за получаване на 4-флуор-2-(((4-метокси-2- пиридинил)метил)тионил)-1н-бензимидазол
KR900005994A (ko) 혈소판 감소증 또는 혈소판 기능장애로 인한 질병 치료용 약학적 제제
DE3873812D1 (de) 3h-1,2,3-triazolo(4,5-d)pyrimidine.
DK443988A (da) Injektionspraeparat indeholdende modificeret tpa
NO863026D0 (no) Fenyletanolaminderivater-preparater med kontinuerlig avgivelse.
JPS6479125A (en) Antitumor agent
ZA891784B (en) Peptides with pharmaceutical activity

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties